Hunan Warrant Pharmaceutical (688799.SH) has obtained the registration certificate for metoprolol tartrate injection.

Hunan Warrant Pharmaceutical (688799.SH) announced that the company has recently received the "Drug Registration Certificate" for the injection of metaraminol bitartrate approved and issued by the National Medical Products Administration. Metaraminol bitartrate injection is used for restoring blood pressure in cases of acute hypotension; it can also be used as adjunctive therapy for cardiac arrest and for maintaining blood pressure after successful resuscitation. In cases of shock due to inadequate blood volume, this product is used as adjunctive therapy for supplementing blood volume during emergencies to raise blood pressure, temporarily maintain cerebral and coronary artery perfusion, until the effects of volume replacement therapy take effect. The company's metaraminol bitartrate injection has obtained the drug registration certificate under the new classification of chemical drugs, Class 3, through the consistency evaluation process.